Business
Aurinia to Participate in 2024 Cantor Fitzgerald Global Healthcare Conference
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the Company’s
About this update from Aurinia Pharmaceuticals Inc
[{"type":"text","content":" ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--\nAurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the Company’s management team will attend the 2024 Cantor Fitzgerald Global Healthcare Conference in New York City, September 17-19, 2024.\n\nAurinia management will host one-on-one meetings with investors and will participate in a fireside chat and Q&A session on Tuesday, September 17th, at 3:05 PM EDT. A live webcast of the session will be available on the Investor section of Aurinia’s website, which can be found here.\n\nAbout Aurinia\n\nAurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy dedicated to the treatment of adult patients with active lupus nephritis. Aurinia is also developing AUR200, a differentiated, potential best-in-class therapy for autoimmune diseases that targets both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand).\nView source version on businesswire.com: https://www.businesswire.com/news/home/20240913634435/en/\n\nMedia & Investor Inquiries:\nAndrea Christopher\nCorporate Communications & Investor Relations\nAurinia Pharmaceuticals Inc.\[email protected]\n\nGeneral Investor Inquiries:\[email protected]\n\nSource: Aurinia Pharmaceuticals Inc.","length":3006,"tagName":"div"}]